Baxter International Inc. (NYSE:BAX) Receives Consensus Rating of "Hold" from Brokerages

Key Points

• Analysts maintain a “Hold” consensus on Baxter International, with nine hold, two sell and two buy ratings among 13 firms. The average 12-month price target is $22.45, below the reported share price of $25.81.
• Baxter’s latest quarterly results exceeded expectations, with EPS of $0.56 versus the $0.37 consensus estimate and revenue of $2.96 billion, up 5.3% year over year. The company issued fiscal 2026 EPS guidance of $1.95 to $2.15.
• The company declared a quarterly dividend of $0.01 per share, representing a $0.04 annualized payout and a 0.2% yield. Institutional investors own approximately 90.19% of Baxter’s shares.

Shares of Baxter International Inc. (NYSE:BAX - Get Free Report) have been given a consensus rating of "Hold" by the thirteen research firms that are presently covering the stock, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, nine have assigned a hold rating and two have assigned a buy rating to the company. The average 12 month price objective among brokers that have covered the stock in the last year is $22.4545.

BAX has been the subject of a number of research analyst reports. Wells Fargo & Company raised their price target on Baxter International from $19.00 to $23.00 and gave the stock an "equal weight" rating in a research note on Friday, July 31st. TD Cowen lifted their price objective on shares of Baxter International from $20.00 to $24.00 and gave the company a "hold" rating in a report on Monday, July 27th. UBS Group increased their target price on shares of Baxter International from $19.00 to $25.00 and gave the stock a "hold" rating in a report on Tuesday, July 28th. Zacks Research raised shares of Baxter International from a "strong sell" rating to a "hold" rating in a research report on Tuesday, August 11th. Finally, Citigroup raised shares of Baxter International from a "sell" rating to a "neutral" rating and upped their price target for the stock from $17.00 to $28.00 in a research report on Friday, July 31st.

Baxter International Price Performance

NYSE:BAX opened at $25.81 on Friday. The firm has a market capitalization of $13.34 billion, a price-to-earnings ratio of -12.47, a PEG ratio of 3.87 and a beta of 0.60. The company has a debt-to-equity ratio of 1.39, a current ratio of 1.95 and a quick ratio of 1.32. The business has a 50 day simple moving average of $24.73 and a 200-day simple moving average of $20.72. Baxter International has a 1 year low of $15.73 and a 1 year high of $30.00.

Baxter International (NYSE:BAX - Get Free Report) last released its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share for the quarter, beating the consensus estimate of $0.37 by $0.19. Baxter International had a positive return on equity of 16.57% and a negative net margin of 9.27%.The company had revenue of $2.96 billion for the quarter, compared to analyst estimates of $2.80 billion. During the same quarter in the prior year, the firm posted $0.59 EPS. Baxter International's quarterly revenue was up 5.3% compared to the same quarter last year. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. Equities analysts forecast that Baxter International will post 2.04 EPS for the current year.

Baxter International Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Shareholders of record on Friday, August 28th will be issued a $0.01 dividend. This represents a $0.04 annualized dividend and a yield of 0.2%. The ex-dividend date of this dividend is Friday, August 28th. Baxter International's dividend payout ratio (DPR) is currently -1.93%.

Institutional Trading of Baxter International

Large investors have recently made changes to their positions in the business. Range Advisory LLC acquired a new position in shares of Baxter International in the 2nd quarter valued at about $242,000. Corient Private Wealth LP increased its stake in shares of Baxter International by 29.8% during the second quarter. Corient Private Wealth LP now owns 40,809 shares of the medical instruments supplier's stock worth $870,000 after purchasing an additional 9,366 shares in the last quarter. Amundi increased its position in shares of Baxter International by 12.2% during the second quarter. Amundi now owns 895,147 shares of the medical instruments supplier's stock worth $19,085,000 after purchasing an additional 97,411 shares in the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Baxter International in the second quarter worth about $964,000. Finally, CYBER HORNET ETFs LLC increased its holdings in shares of Baxter International by 52.4% in the second quarter. CYBER HORNET ETFs LLC now owns 2,153 shares of the medical instruments supplier's stock valued at $46,000 after purchasing an additional 740 shares during the last quarter. 90.19% of the stock is owned by hedge funds and other institutional investors.

About Baxter International

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company's primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter's offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source